健脾化瘀解毒中药复方对溃疡性结肠炎患者血清细胞因子EGF、TGF-β1及TNF-α的影响

Effects of Jianpi Huayu Jiedu decoction on the expression of EGF, TGF-β1 and TNF-α in patients with ulcerative colitis

关键词:  健脾化瘀解毒  溃疡性结肠炎  血清表皮生长因子  转化生长因子-β1  肿瘤坏死因子-α

Key words:  JPHYJD  ulcerative colitis  EGF  TGF-β1  TNF-α

摘要:

[目的]通过观察健脾化瘀解毒复方治疗溃疡性结肠炎（UC）的临床疗效，进一步探讨其分子生物学作用机制。[方法]采用随机、阳性药平行对照方法，将60例轻中度溃疡性结肠炎患者分为观察组30例和对照组30例，观察组给予健脾化瘀解毒复方中药，对照组给予美沙拉嗪4 g/d，疗程为3个月，观察治疗前后高敏C反应蛋白（CRP）、血小板（PLT）、Mayo评分的变化，并检测血清中表皮生长因子（EGF）、转化生长因子-β1（TGF-β1）、肿瘤坏死因子-α（TNF-α）的表达水平。[结果]血清CRP值、PLT、Mayo评分、EGF、TGF-β1及TNF-α表达治疗前观察组和对照组无统计学差异（P>0.05），与治疗前相比，健脾化瘀解毒复方组和观察组治疗后CRP值、PLT、Mayo评分降低、EGF升高、TGF-β1及TNF-α表达降低，均具有统计学差异（P<0.01）；与对照组相比，健脾化瘀解毒复方组PLT、Mayo评分、TNF-α均具有统计学差异（P<0.05）；且观察组治疗有效率为93.1%优于对照组的76.7%。[结论]健脾化瘀解毒复方具有良好的抗溃疡性结肠炎的作用，其机制可能与调节血清EGF、TGF-β1、TNF-α的表达有关，其抗炎效果优于美沙拉嗪组。

Abstract:

[Objective] To investigate the mechanism of molecular biology of Jianpi Huayu Jiedu (JPHYJD) decoction on Patients with UC based on the clinical curative effect.[Methods] Detect serum CRP, platelet, Mayo score, the levels of serum Epidermal growth factor (EGF), Transforming growthfactor β1(TGF-β1) and Tumor necrosis factor alpha (TNF-α) on 60 patients with mild-to-moderate UC before and after the treatment of JPHYJD decoction and mesalazine.[Results] Serum CRP value, platelets, Mayo score, the expression of EGF, TGF-β1 and TNF-α have no statistical difference between treatment group and control group (P>0.05). Compared with before treatment, these indicators on patients with JPHYJD decoction and mesalazine are significant differences (P<0.01) and JPHYJD decoction have statistical differences for mesalazine on platelets, Mayo score and TNF-α (P<0.05). The observation group and control group has the significant effective rate of 93.1% and 76.7% (P<0.05).[Conclusion] The mechanism of JPHYJD decoction for the treatment of ulcerative colitis may be related to regulating the expressions serum EGF,TGF-β1 and TNF-α, and anti-inflammatory effect is better than mesalazine.